Cretostimogene Grenadenorepvec not checked

CG Oncology, Inc. · CG0070

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
3 active
7 in total
Targets
—
None known yet

What this is

How it works
A gene therapy: delivers a gene into the patient's cells so they make a protein they lack.-gene: gene therapy substances WHO name stem
Tested for
Non Muscle Invasive Bladder Cancer (2 trials), Urologic Cancer, Bladder Cancer, Urothelial Carcinoma, High-grade Ta/ T1 Papillary Disease Bladder Cancer, High-Risk Non-Muscle-Invasive Bladder Cancer
Main trialPhase 3
“This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.”In the company’s words, NCT06111235 on ClinicalTrials.gov
Other names
CG0070 · oncolytic virus · GM-CSF expression · adenoviral vector · Adenovirus with GMCSF expression · DDM

Other drugs for Non Muscle Invasive Bladder Cancer

All 26 drugs for Non Muscle Invasive Bladder Cancer

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials7

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Nov 2026 A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
Phase 3Active, not recruiting 16 Jun 2030 Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Phase 2Recruiting 31 Mar 2027 Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Phase 2/3Terminated Jun 2016 Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
Phase 2Withdrawn Mar 2015 Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer
Phase 2Completed Aug 2018 Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure
Phase 2Completed 7 Mar 2023 Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Cretostimogene Grenadenorepvec

Following is part of Solo: you see every change to Cretostimogene Grenadenorepvec the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in